| 21.05 10:09 | dpa-AFX: ANALYSE-FLASH: UBS belässt Astrazeneca auf 'Sell' - Ziel 10500 Pence |
| 21.05 10:09 | dpa-AFX: UBS belässt Astrazeneca auf 'Sell' - Ziel 10500 Pence |
| 21.05 09:32 | dpa-AFX: Astrazeneca will Umsatz bis 2030 fast verdoppeln |
| 21.05 09:32 | Astrazeneca will Umsatz bis 2030 fast verdoppeln |
| 21.05 09:27 | dpa-AFX: Astrazeneca will Umsatz bis 2030 fast verdoppeln |
| 21.05 08:43 | dpa-AFX: AstraZeneca Targets $80 Bln Revenue By 2030, Plans To Launch 20 New Medicines |
| 21.05 08:37 | Astrazeneca will Umsatz bis 2030 auf 80 Mrd USD steigern |
| 21.05 08:17 | dpa-AFX: *ASTRAZENECA SETS AMBITION TO DELIVER $80 BLN TOTAL REVENUE BY 2030 |
| 21.05 08:02 | dpa-AFX: *ASTRAZENECA EXPECTS TO LAUNCH 20 NEW MEDICINES BY 2030 |
| 21.05 08:01 | dpa-AFX: *ASTRAZENECA AIMS TO DELIVER $80 BLN TOTAL REVENUE BY 2030 AND SUSTAINED GROWTH POST 2030 |
| 20.05 11:14 | dpa-AFX: ANALYSE-FLASH: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 20.05 11:14 | dpa-AFX: JPMorgan belässt Astrazeneca auf 'Overweight' - Ziel 13000 Pence |
| 20.05 08:44 | Astrazeneca plant 1,5 Mrd USD teure Produktionsanlage in Singapur |
| 20.05 08:21 | dpa-AFX: AstraZeneca To Build $1.5 Bln Manufacturing Facility In Singapore For Antibody Drug Conjugates |
| 20.05 08:05 | dpa-AFX: *ASTRAZENECA PLANS $1.5 BLN MANUFACTURING FACILITY FOR ANTIBODY DRUG CONJUGATES IN SINGAPORE |
| 20.05 08:04 | dpa-AFX: *ASTRAZENECA TO START BUILDING ADCS FACILITY IN SINGAPORE BY 2024, OPERATIONAL BY 2029 |
| 20.05 08:02 | dpa-AFX: *ASTRAZENECA INTENDS TO BUILD $1.5 BLN MANUFACTURING FACILITY IN SINGAPORE FOR ANTIBODY DRUG CONJUGATES |
| 20.05 03:38 | dpa-AFX: AstraZeneca: New Data Shows Tezspire's Role In Future COPD Treatment |
| 16.05 09:18 | dpa-AFX: AZN:Phase III Trial Of Sipavibart Met Main Goal In Preventing COVID-19 In Immunocompromised Patients |
| 16.05 08:27 | dpa-AFX: *ASTRAZENECA SAYS SUPERNOVA PHASE III TRIAL OF SIPAVIBART MEETS PRIMARY ENDPOINTS IN PREVENTING COVID-19 |
|
|
